AC Immune Ltd. Daily Stock Analysis

Daily Stock Analysis, ACIU, AC Immune Ltd, priceseries

AC Immune Ltd. Daily Stock Analysis
Stock Information
Open
3.59
Close
3.55
High
3.66
Low
3.50
Previous Close
3.78
Daily Price Gain
-0.23
YTD High
5.21
YTD High Date
Jan 4, 2022
YTD Low
3.50
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.61
YTD Gain
-31.20%
52 Week High
12.61
52 Week High Date
Aug 31, 2021
52 Week Low
3.50
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-4.08
52 Week Gain
-53.47%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Aug 30. 2017
7.63
Sep 21. 2017
10.29
15 Trading Days
34.92%
Link
LONG
Oct 11. 2018
8.01
Oct 23. 2018
8.73
8 Trading Days
9.00%
Link
LONG
Nov 15. 2018
9.65
Dec 6. 2018
10.52
13 Trading Days
8.99%
Link
LONG
Nov 13. 2019
6.53
Dec 2. 2019
7.61
12 Trading Days
16.47%
Link
LONG
Mar 23. 2020
5.38
Apr 7. 2020
6.89
11 Trading Days
28.12%
Link
LONG
Jan 5. 2021
5.50
Jan 27. 2021
5.89
15 Trading Days
7.16%
Link
LONG
Feb 2. 2021
6.60
Feb 23. 2021
7.45
14 Trading Days
12.92%
Link
LONG
Jun 1. 2021
6.37
Jun 2. 2021
6.77
1 Trading Days
6.26%
Link
LONG
Jun 16. 2021
7.41
Jun 30. 2021
7.96
10 Trading Days
7.40%
Link
LONG
Aug 23. 2021
6.72
Sep 2. 2021
7.15
8 Trading Days
6.40%
Link
LONG
Oct 26. 2021
6.23
Nov 10. 2021
6.72
11 Trading Days
7.88%
Link
Company Information
Stock Symbol
ACIU
Exchange
NasdaqGM
Company URL
http://www.acimmune.com
Company Phone
41 21 345 91 21
CEO
Andrea Pfeifer
Headquarters
-
Business Address
EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, SWITZERLAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001651625
About

AC Immune SA is a clinical stage biopharmaceutical company, which engages in leveraging two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. It's products include: crenezumab, humanized, monoclonal, conformation-specific anti-Abeta antibody that developed using the SupraAntigen™ platform. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, and Andrea Pfeifer on February 13, 2003 and is headquartered in Lausanne, Switzerland.

Description

AC Immune SA is a biopharmaceutical company. It is engaged in leveraging its two proprietary technology platforms to discover, design and develop novel, proprietary medicines for treatment of neurodegenerative diseases.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading